Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2009
04/09/2009US20090092543 Methods of treating and preventing inflammatory bowel disease involving il-13 and nkt cells
04/09/2009DE4435114B4 Verwendung einer wässrigen Zusammensetzung, die kokosfettsäurediethanolamid enthält, für eine Pestizidzusammensetzung Use of an aqueous composition containing coconut fatty acid diethanolamide, a pesticidal composition
04/09/2009DE19681421B4 Vorrichtung und Bereitstellungsverfahren für eine transdermale Elektrotransport-Abgabe von Fentanyl und Sufentanil Apparatus and method for providing a transdermal electrotransport delivery of fentanyl and sufentanil
04/09/2009DE19543553B4 VP-Antigene des JC-Virus VP-antigens of the JC virus
04/09/2009DE10223934B4 Verwendung eines Desinfektionsmittels zur Inaktivierung von Hepatitis B-Virus Use of a disinfectant for the inactivation of hepatitis B virus
04/09/2009DE102007048080A1 Biomedizinische Schaumartikel Biomedical foam article
04/09/2009DE102007047738A1 Imidazolderivate Imidazole derivatives
04/09/2009DE102007047735A1 Thiazolderivate Thiazole derivatives
04/09/2009DE102007047608A1 19-nor-Progesterone zur Kontrazeption 19-nor-progesterone contraceptive
04/09/2009DE102007046202A1 Medium for preventing or relieving pain, muscular strain particularly in muscle, for improvement of immune condition, wound healing or for reduction or recovery of arteriosclerosis, has mixture of tocotrienols and gamma linolenic acid
04/09/2009DE102007044583A1 Composition, useful for wound treatment in veterinary field, as spray in button probe, and as ointment or cream, comprises hyaluronic acid, urea and colloidal silver
04/09/2009DE102007044582A1 Zusammensetzung für Wundbehandlungen im Humanbereich Composition for the treatment of wounds in the human area
04/09/2009DE102007041476A1 Aptamere, die an ein an der Hämostase beteiligtes Zielmolekül binden Aptamers that bind to a party to the hemostasis target molecule
04/09/2009CA2739523A1 Treatment of dissection, aneurysm, and atherosclerosis using granzyme b inhibitors
04/09/2009CA2738980A1 Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use
04/09/2009CA2738070A1 Novel compounds for the treatment or alleviation of edema, and methods for their use
04/09/2009CA2715080A1 Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
04/09/2009CA2706254A1 Novel chondroitin sulfate having decreased molecular weight and use thereof
04/09/2009CA2706241A1 Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain
04/09/2009CA2704347A1 A cancer sensitizer comprising chlorogenic acid
04/09/2009CA2703501A1 Orodispersible tablets
04/09/2009CA2702032A1 Skin property-improving therapeutic agent comprising a morphinan derivative or any of its pharmacologically permissible acid addition salts as an active ingredient
04/09/2009CA2702028A1 Tripartite rnai constructs
04/09/2009CA2701845A1 Novel sirna structures
04/09/2009CA2701844A1 Composition and method for treatment or prevention of benign prostatic hyperplasia and lower urinary tract symptoms
04/09/2009CA2701768A1 Thiophene-2-carboxamide derivatives as modulators of ccr9 receptor
04/09/2009CA2701721A1 Ophthalmic compositions based on tamarind seed polysaccharide and hyaluronic acid
04/09/2009CA2701713A1 Hydrocortisone derivatives and use thereof for therapeutic or cosmetic indications
04/09/2009CA2701712A1 Method for preparing stable hop powder
04/09/2009CA2701649A1 Method of treating polycystic kidney diseases with ceramide derivatives
04/09/2009CA2701630A1 Quinolone analogs and methods related thereto
04/09/2009CA2701620A1 Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer
04/09/2009CA2701618A1 Pharmaceutical composition for inhibiting amyloid-beta protein accumulation
04/09/2009CA2701605A1 Granule, tablet and methods for producing the same
04/09/2009CA2701581A1 Pyrimidine substituted purine derivatives
04/09/2009CA2701579A1 Novel aryl potassium channel blockers and uses thereof
04/09/2009CA2701555A1 Systemic pro-hemostatic effect of sympathicomimetics with agonistic effects on .alpha.-adrenergic and/or .beta.-adrenergic receptors of the sympathetic nervous system, related to improved clot strength
04/09/2009CA2701547A1 Micromirs
04/09/2009CA2701414A1 Process for the preparation of zolmitriptan, salts and solvates thereof
04/09/2009CA2701406A1 Benzoxazinone derivative
04/09/2009CA2701404A1 Compositions comprising cetirizine and a non beta-2-adrenoreceptor agonist, a beta-2-adrenoreceptor agonist or an anti-inflammatory and the use thereof for the treatment of respiratory disorders
04/09/2009CA2701397A1 Nerve cell death inhibitor
04/09/2009CA2701386A1 Imidazo[1,2-.alpha.]quinoxalines and derivatives thereof for treating cancers
04/09/2009CA2701368A1 A composition containing non-psychotropic cannabinoids for the treatment of inflammatory diseases.
04/09/2009CA2701356A1 Potent combinations of zidovudine and drugs that select for the k65r mutation in the hiv polymerase
04/09/2009CA2701355A1 Triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
04/09/2009CA2701323A1 Composition and method for dermal regeneration
04/09/2009CA2701249A1 Stable bicarbonate ion-containing drug solution
04/09/2009CA2701214A1 Tetrazole-substituted aryl amide derivatives and uses thereof
04/09/2009CA2701203A1 N-substituted oxindoline derivatives as calcium channel blockers
04/09/2009CA2701179A1 Compositions and methods for enhancing cognitive function
04/09/2009CA2701172A1 Methods of treating neurological autoimmune disorders with cyclophosphamide
04/09/2009CA2701128A1 Antisense modulation of fibroblast growth factor receptor 4 expression
04/09/2009CA2701126A1 Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease
04/09/2009CA2701124A1 C-met protein kinase inhibitors
04/09/2009CA2701120A1 Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof
04/09/2009CA2701118A1 Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of-life in lung diseases
04/09/2009CA2701116A1 Alkoxy compounds for disease treatment
04/09/2009CA2701115A1 N-hydroxy-naphthalene dicarboxamide and n-hydroxy-biphenyl-dicarboxamide compounds as histone deacetylase inhibitors
04/09/2009CA2701075A1 Therapeutic use of diaminophenothiazines
04/09/2009CA2701025A1 Anti-bacterial pyrocatechols and related methods
04/09/2009CA2701023A1 Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
04/09/2009CA2701020A1 Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof
04/09/2009CA2700974A1 Substituted aryl sulfone derivatives as calcium channel blockers
04/09/2009CA2700972A1 N-substituted oxindoline derivatives as calcium channel blockers
04/09/2009CA2700964A1 Gamma secretase modulators
04/09/2009CA2700963A1 Oxypiperidine derivatives and methods of use thereof
04/09/2009CA2700953A1 Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
04/09/2009CA2700928A1 Novel compounds
04/09/2009CA2700903A1 Parp inhibitor compounds, compositions and methods of use
04/09/2009CA2700867A1 Method for stabilizing quercetin
04/09/2009CA2700857A1 Hdac inhibitors
04/09/2009CA2700762A1 Pyridine derivatives for the treatment of amyloid-related diseases
04/09/2009CA2700724A1 Modulators of muscarinic receptors
04/09/2009CA2700691A1 New biaryl derivatives
04/09/2009CA2700530A1 Antifungal agents
04/09/2009CA2700526A1 New compounds as adenosine a1 receptor antagonists
04/09/2009CA2700410A1 Treatment of proliferative disorders using antibodies to psma
04/09/2009CA2700380A1 Compositions and methods for altering alpha- and beta-tocotrienol content using multiple transgenes
04/09/2009CA2700181A1 Steroidal [3, 2-c] pyrazole compounds, with glucocorticoid activity
04/09/2009CA2699625A1 Cyclopropyl aryl amide derivatives and uses thereof
04/09/2009CA2699601A1 Nlrr-1 antagonists and uses thereof
04/09/2009CA2699138A1 Compounds and methods for pharmaceutical use
04/09/2009CA2698928A1 Compounds and methods for treating zinc matrix metalloprotease dependent diseases
04/09/2009CA2698330A1 Galenical formulations of organic compounds
04/09/2009CA2697125A1 Use of at least one oxime derivative of cholest-4-en-3-one as antioxidants
04/09/2009CA2696863A1 Oxadiazole derivatives
04/09/2009CA2696829A1 Oxadiazole diaryl compounds
04/09/2009CA2695950A1 Compositions containing nucleosides and manganese and their uses
04/09/2009CA2694843A1 Three-functional pseudo-peptidic reagent, and uses and applications thereof
04/09/2009CA2694322A1 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives, preparation and therapeutic use thereof
04/09/2009CA2694313A1 Derivatives of 1-oxo-1,2-dihydroisoquinoline-5-carboxamides and of 4-oxo-3,4-dihydroquinazoline-8-carboxamides, preparation thereof and application thereof in therapeutics
04/09/2009CA2694288A1 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives, preparation and therapeutic use thereof
04/09/2009CA2694148A1 Use of at least one oxime derivative of 3,5-seco-4-norcholestane as antioxidants
04/08/2009EP2045322A1 Double-muscling in mammals
04/08/2009EP2045258A1 3'-ethynylcytidine derivative
04/08/2009EP2045256A1 2'-cyanopyrimidine nucleoside compound
04/08/2009EP2045253A1 a-AMINO ACID DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT
04/08/2009EP2045251A1 Compound that can inhibit ubc13-uev interactions, pharmaceutical compositions and therapeutic uses
04/08/2009EP2045250A1 Ring-substituted phenyl pyrrole aminoguanidine derivatives